The FDA has finalized guidance on electronically submitting reports of adverse events from bioavailability and bioequivalence studies to the agency's Adverse Event Reporting System. The guidance outlines submission methods and how the FDA will notify manufacturers that it received individual case safety reports, as well as how to submit follow-up reports, describe drug exposure, and differentiate post-market and premarket ICSRs.